Aileron Therapeutics Inc Stock Price, News & Analysis

Aileron Therapeutics (Nasdaq: ALRN) announced that Dr. Manuel Aivado will present a company overview at two upcoming virtual conferences: the H.C. Wainwright BIOCONNECT Conference from January 10-12, 2022, and the Emerging Growth Conference on January 5, 2022. The H.C. Wainwright presentation will be available on-demand starting January 10 at 7:00 a.m. ET. Aileron's ALRN-6924 is a first-in-class chemoprotective agent targeting p53-mutated cancers, aiming to improve chemotherapy tolerability while preserving healthy cells.

Aileron Therapeutics (NASDAQ:ALRN) expressed deep sorrow over the passing of Nobel Laureate Robert H. Grubbs, Ph.D., a member of its Scientific Advisory Board since 2011. Grubbs, a prominent chemist, significantly influenced Aileron's stapled peptide technology and the chemoprotective agent ALRN-6924.

His contributions to metathesis reactions enabled the development of specialized drugs and plastics. Aileron vows to honor his legacy by advancing ALRN-6924, aimed at improving the chemotherapy experience for patients with p53-mutated cancers.

Aileron Therapeutics (NASDAQ:ALRN) continues its Phase 1b trial of ALRN-6924 for p53-mutated non-small cell lung cancer (NSCLC). Planned data readouts include interim results in 2Q22 and topline results in 4Q22. As of September 30, 2021, the company reported $52.2 million in cash, expected to fund operations until mid-2023. R&D expenses rose to $4.3 million, while net loss increased to $6.7 million. ALRN-6924 aims to protect healthy cells from chemotherapy-induced side effects, potentially addressing a critical need for cancer patients.

Aileron Therapeutics has presented new preclinical data at the AACR-NCI-EORTC conference, highlighting ALRN-6924's potential as a chemoprotective and radioprotective agent for patients with p53-mutated cancers undergoing chemotherapy. The data shows that ALRN-6924 activates p21, which may help protect healthy cells from chemotherapy and radiation-induced toxicities. The company is currently conducting a Phase 1b clinical trial in patients with advanced non-small cell lung cancer, aiming to reduce chemotherapy side effects while maintaining efficacy.

Aileron Therapeutics (ALRN) announced new preclinical data on its investigational drug ALRN-6924, showcasing its potential as a radioprotective agent against radiation-induced toxicities. ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, aims to protect healthy cells during chemotherapy for patients with p53-mutated cancers. The data will be presented at the AACR-NCI-EORTC conference on October 7, 2021. The Phase 1b trial for ALRN-6924 is underway, evaluating its effectiveness in non-small cell lung cancer patients treated with carboplatin and pemetrexed.

Aileron Therapeutics (ALRN) announced positive outcomes from its Phase 1b trial of ALRN-6924 in small cell lung cancer (SCLC) patients receiving topotecan, showing significant reductions in chemotherapy-induced neutropenia, thrombocytopenia, and anemia compared to historical controls. Preliminary findings from a Phase 1 pharmacology study confirmed the optimal dose of ALRN-6924 at 0.3 mg/kg, demonstrating its pharmacodynamic effects. These results inform future studies of ALRN-6924 as a chemoprotective agent across various p53-mutated cancers.

Aileron Therapeutics (Nasdaq: ALRN) announced its upcoming presentations at the ESMO Virtual Congress 2021, including preliminary data from a Phase 1 study of ALRN-6924 in healthy volunteers and final results from a Phase 1b study in patients with small cell lung cancer (SCLC) receiving topotecan. ALRN-6924 aims to protect healthy cells from chemotherapy-induced side effects while targeting cancer cells. The findings support ongoing and future studies in patients with p53-mutated cancers.

Aileron Therapeutics (Nasdaq: ALRN) announced that CEO Manuel Aivado will present at the H.C. Wainwright Virtual Global Investment Conference from September 13-15, 2021. His presentation will cover the progress of ALRN-6924, a selective chemoprotective agent targeting p53-mutated cancers. The on-demand presentation will be available to registered attendees starting September 13, 2021, at 7 AM ET and accessible for 30 days on Aileron's website. Aileron aims to enhance chemotherapy tolerability and improve patients' quality of life by protecting healthy cells during treatment.

Aileron Therapeutics (Nasdaq: ALRN) reported initial findings from its study of ALRN-6924, showcasing that a 0.3 mg/kg dose was well tolerated and induced p53-mediated p21 in normal bone marrow cells. This Phase 1b trial aims to evaluate ALRN-6924 as a chemoprotective agent for patients with advanced p53-mutated non-small cell lung cancer (NSCLC). Nearly 1 million patients in the U.S. are diagnosed yearly with p53-mutated cancers. Aileron also plans to present more data from this study at the upcoming ESMO Congress in September 2021.